ATE133452T1 - Humanisierte immunglobuline, deren herstellung und verwendung - Google Patents

Humanisierte immunglobuline, deren herstellung und verwendung

Info

Publication number
ATE133452T1
ATE133452T1 AT90903576T AT90903576T ATE133452T1 AT E133452 T1 ATE133452 T1 AT E133452T1 AT 90903576 T AT90903576 T AT 90903576T AT 90903576 T AT90903576 T AT 90903576T AT E133452 T1 ATE133452 T1 AT E133452T1
Authority
AT
Austria
Prior art keywords
human
cdr
receptor
tac
nucleic acid
Prior art date
Application number
AT90903576T
Other languages
English (en)
Inventor
Cary L Queen
Harold Edwin Selick
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26966505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE133452(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Application granted granted Critical
Publication of ATE133452T1 publication Critical patent/ATE133452T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90903576T 1988-12-28 1989-12-28 Humanisierte immunglobuline, deren herstellung und verwendung ATE133452T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29097588A 1988-12-28 1988-12-28
US31025289A 1989-02-13 1989-02-13

Publications (1)

Publication Number Publication Date
ATE133452T1 true ATE133452T1 (de) 1996-02-15

Family

ID=26966505

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90903576T ATE133452T1 (de) 1988-12-28 1989-12-28 Humanisierte immunglobuline, deren herstellung und verwendung
AT95105609T ATE183753T1 (de) 1988-12-28 1989-12-28 Herstellung humanähnlicher immunoglobuline und entsprechender polynukleotide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95105609T ATE183753T1 (de) 1988-12-28 1989-12-28 Herstellung humanähnlicher immunoglobuline und entsprechender polynukleotide

Country Status (32)

Country Link
EP (6) EP1491556B1 (de)
JP (6) JP2828340B2 (de)
KR (1) KR0178385B1 (de)
CN (1) CN1057013C (de)
AT (2) ATE133452T1 (de)
AU (1) AU647383B2 (de)
BG (1) BG61095B2 (de)
CA (2) CA2006865C (de)
CZ (1) CZ418691A3 (de)
DD (1) DD296964A5 (de)
DE (14) DE04076439T1 (de)
DK (2) DK119191A (de)
ES (5) ES2492815T3 (de)
FI (1) FI108797B (de)
FR (1) FR14C0070I1 (de)
HK (1) HK1014718A1 (de)
HR (1) HRP920500B1 (de)
HU (1) HU211174A9 (de)
IE (1) IE20000331A1 (de)
IL (2) IL162181A (de)
LU (8) LU90411I2 (de)
MC (1) MC2146A1 (de)
NL (8) NL990020I2 (de)
NO (9) NO310473B1 (de)
NZ (2) NZ231984A (de)
PT (1) PT92758B (de)
RU (1) RU2126046C1 (de)
SG (1) SG78258A1 (de)
SI (1) SI8912489B (de)
WO (1) WO1990007861A1 (de)
YU (1) YU48700B (de)
ZA (1) ZA899956B (de)

Families Citing this family (967)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GR1001050B (el) * 1990-01-09 1993-04-28 Protein Design Labs Inc Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
HU219537B (hu) * 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
IE920716A1 (en) * 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
JP3213314B2 (ja) * 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン 幹細胞因子レセプターに対するモノクローナル抗体
RU2139351C1 (ru) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9115010D0 (en) * 1991-07-11 1991-08-28 Wellcome Found Antibody
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
HU220295B (hu) * 1991-07-25 2001-11-28 Idec Pharmaceuticals Corp. Antigénkészítmények és ezek alkalmazása citotoxikus T-limfocita reakciók indukálására
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
EP0528767B1 (de) * 1991-08-21 2000-01-12 Novartis AG Antikörperderivate
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
JP3024311B2 (ja) * 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP0625200B1 (de) * 1992-02-06 2005-05-11 Chiron Corporation Marker für krebs und biosynthetisches bindeprotein dafür
GB9203459D0 (en) * 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
DE669986T1 (de) * 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
WO1994025067A1 (en) * 1993-05-04 1994-11-10 Cytel Corporation Antibodies to p-selectin and their uses
WO1994028025A1 (en) 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU695726B2 (en) * 1993-09-07 1998-08-20 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
EP0729976A1 (de) 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Rekonstituierter humaner antikoerper gegen humane medulloblastomzellen
AU2185195A (en) * 1993-11-30 1995-06-19 Protein Design Labs, Inc. Reperfusion therapy using antibodies to L-selectin
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
DK1759709T3 (da) * 1994-01-25 2013-06-10 Elan Pharm Inc Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0753065B1 (de) 1994-03-29 2003-05-14 Celltech Therapeutics Limited Antikörper gegen e-selektin
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
EP0696455A1 (de) * 1994-08-11 1996-02-14 Cellena (Cell Engineering) A.G. Transferrin Zusammensetzungen zur Erleichterung der Nebenwirkungen der cytotoxischen Medikamente
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
WO1996040249A1 (en) * 1995-06-07 1996-12-19 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
GB9600660D0 (en) 1996-01-12 1996-03-13 Ciba Geigy Ag Protein
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6713305B1 (en) 1996-04-29 2004-03-30 Novartis Ag Metastasis-associated antigen and antibodies thereto
WO1997046589A2 (en) 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
US6833255B1 (en) 1996-07-24 2004-12-21 Novartis, Ag Drosophila melanogaster p70 S6 kinase
US6534311B2 (en) 1996-07-24 2003-03-18 Novartis Ag Drosophila melanogaster p70S6 kinase
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2264968A1 (en) * 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US20020160005A1 (en) 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU743758B2 (en) 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
TR199902800T2 (xx) 1997-05-15 2000-04-21 Chugai Seiyaku Kabushiki Kaisha Ka�eksiyi tedavi edici madde.
CA2290485C (en) * 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
JP4891477B2 (ja) 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． 血管新生及び／または既存細動脈網から側枝動脈及び／または他の動脈の発達の調節に関する方法
EP1020522B1 (de) * 1997-10-03 2007-09-19 Chugai Seiyaku Kabushiki Kaisha Natürlicher menschlicher antikörper
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1745799B1 (de) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Zusammensetzungen und Verfahren zur Behandlung von Tumoren
CA2325346A1 (en) 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
HU228180B1 (hu) 1998-08-11 2013-01-28 Biogen Idec Inc Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
JP4689781B2 (ja) * 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 アミノ酸輸送蛋白及びその遺伝子
SI1113810T1 (sl) 1998-09-14 2009-04-30 Univ Texas Postopki za zdravljenje multiplega mieloma in kostne resorpcije, inducirane z mielomom, z uporabo antagonistov integrin/receptorske vezave
EP1117808B1 (de) 1998-10-06 2004-12-29 Mark Aaron Emalfarb Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
EP1939215A1 (de) 1998-10-22 2008-07-02 The University of Montana Omp85-Proteien von Neisseria Gonorrhoeae und Neisseria Meningitidis, Zusammensetzungen damit und ihre Verwendungsverfahren
DK1616572T3 (da) 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
EA006681B1 (ru) 1999-04-22 2006-02-24 Байоджен Айдек Ма Инк. Применение антагонистов взаимодействия vla-4 и альфа-4-бета-7 с соответствующими альфа-4-лигандами для лечения фиброза
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000072881A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
ATE388167T1 (de) * 1999-09-30 2008-03-15 Kyowa Hakko Kogyo Kk Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
DK1242118T3 (da) 1999-12-16 2010-01-11 Biogen Idec Inc Fremgangsmåder til behandling af iskæmisk eller hæmorrhagisk beskadigelse af centralnervesystemet under anvendelse af anti-alfa4-integrin-antagonister
ATE474854T1 (de) 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
AU2001240020B9 (en) 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
AU2001233277B2 (en) * 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
ATE420661T1 (de) 2000-04-28 2009-01-15 Chugai Pharmaceutical Co Ltd Zellproliferation-inhibitoren
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
ATE412185T1 (de) 2000-04-29 2008-11-15 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2002028480A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
HUP0400986A3 (en) * 2001-04-06 2012-09-28 Univ Bristol Use of cd25 binding molecules in steroid-resistant patients
US7358054B2 (en) 2001-04-13 2008-04-15 Biogen Idec Ma Inc. Antibodies to VLA-1
WO2002094879A1 (en) * 2001-05-18 2002-11-28 Boehringer Ingelheim International Gmbh Antibodies specific for cd44v6
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
JP4675512B2 (ja) * 2001-07-10 2011-04-27 三井化学株式会社 熱殺菌方法
EP1578917A4 (de) 2001-07-19 2008-01-23 Perlan Therapeutics Inc Multimere proteine und verfahren zu deren herstellung und verwendung
WO2003014162A1 (en) * 2001-08-03 2003-02-20 Medical & Biological Laboratories Co., Ltd. ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
AU2002329775C1 (en) 2001-08-17 2011-04-07 Eli Lilly And Company Assay method for alzheimer's disease
EP3467117B1 (de) 2001-09-20 2020-07-15 Immunex Corporation Auswahl von zellen mit expression von heteromeren polypeptiden
US7241873B2 (en) 2001-09-25 2007-07-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-osteopontin antibody and use thereof
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
CN1585778A (zh) * 2001-11-12 2005-02-23 默克专利有限公司 修饰的抗－TNFα抗体
EP1944043A1 (de) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
BR0214350A (pt) 2001-11-21 2005-05-10 Univ Pennsylvania Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
WO2003048083A2 (en) 2001-11-30 2003-06-12 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
WO2003048321A2 (en) * 2001-12-03 2003-06-12 Alexion Pharmaceuticals, Inc. Hybrid antibodies
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
JP2006508631A (ja) * 2002-02-22 2006-03-16 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド 抗ｃｃｒ５抗体
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
WO2003080674A1 (en) 2002-03-20 2003-10-02 Pharmacia Corporation Antibody disulfide isomers, use thereof, and methods of analyzing same
CA2480059C (en) * 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
ATE473284T1 (de) 2002-05-14 2010-07-15 Martek Biosciences Corp Carotinsynthase-gen und dessen verwendung
JP4418745B2 (ja) 2002-05-28 2010-02-24 ユセベ ファルマ ソシエテ アノニム 抗体ｐｅｇ位置異性体、それを含む組成物及びその使用
ATE483472T1 (de) * 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2003106485A1 (en) 2002-06-14 2003-12-24 Monier Tadros Method for the production of protamine
GB0213745D0 (en) 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
JP2005535636A (ja) * 2002-06-28 2005-11-24 アメリカ合衆国 インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
KR20050086628A (ko) 2002-11-15 2005-08-30 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
EP1660535A2 (de) 2002-11-27 2006-05-31 Minerva Biotechnologies Corporation Verfahren und zusammensetzungen zur diagnose und behandlung von krebs (muc1)
SI1572744T1 (sl) 2002-12-16 2010-09-30 Genentech Inc Imunoglobulinske variante in njihove uporabe
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP3527228A1 (de) 2003-01-24 2019-08-21 Biogen MA Inc. Zusammensetzung zur behandlung von demyelinisierungskrankheiten und lähmungen durch verabreichung von remyelinisierungsmitteln
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US7939076B2 (en) 2003-04-23 2011-05-10 Medarex, Inc. Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist
ES2368737T3 (es) * 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
EP1633189B1 (de) 2003-05-19 2017-07-05 Prothena Biosciences Limited Verkürzte fragmente von alpha-synuklein bei lbd-krankheit
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
NZ544486A (en) 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
ES2751414T5 (es) 2003-07-08 2024-04-23 Novartis Pharma Ag Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
CN103880955A (zh) 2003-07-18 2014-06-25 安姆根有限公司 肝细胞生长因子的特异性结合物
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
WO2005044857A1 (ja) * 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha ヒト化抗cd47抗体
EP1687325A4 (de) 2003-11-12 2008-11-12 Progenics Pharm Inc Neue, für glykoproteine des hepatitis c virus kodierende sequenzen
US7700737B2 (en) 2003-12-05 2010-04-20 Multimmune Gmbh Therapeutic and diagnostic anti-Hsp70 antibodies
WO2005056599A2 (en) 2003-12-08 2005-06-23 Morphotek, Inc. Antibodies that specifically bind pms2
AU2004299053B2 (en) 2003-12-15 2011-01-06 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101352853B1 (ko) 2004-01-07 2014-02-04 조마 테크놀로지 리미티드 Ｍ-ｃｓｆ-특이적 단일클론 항체 및 그것의 사용
JPWO2005068504A1 (ja) 2004-01-19 2008-01-10 株式会社医学生物学研究所 炎症性サイトカイン抑制剤
AU2005216013B2 (en) 2004-01-30 2010-11-11 Dana Farber Cancer Institute Method for determination and quantification of radiation or genotoxin exposure
CA2561531C (en) 2004-02-10 2017-05-02 The Regents Of The University Of Colorado Inhibition of factor b, the alternative complement pathway and methods related thereto
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
EP1717250A4 (de) 2004-02-20 2008-10-01 Immuno Biological Lab Co Ltd Monoklonaler antikörper und dessen verwendung
EP2287194B1 (de) 2004-03-12 2016-10-26 Vasgene Therapeutics, Inc. EphB4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
CA2564989C (en) 2004-03-19 2014-05-27 Amgen, Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
EP2394662B1 (de) 2004-04-02 2018-03-21 The Regents of The University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
US8492106B2 (en) 2004-05-24 2013-07-23 Universitat Zu Koln Identification methods for ergothioneine transporter modulators and therapeutic uses thereof
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
PT2662390T (pt) 2004-06-21 2017-10-09 Squibb & Sons Llc Anticorpos contra recetor 1 do interferão alfa e as suas utilizações
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
EP1791563A4 (de) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154-antikörper
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
FI20041204A0 (fi) 2004-09-16 2004-09-16 Riikka Lund Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
ATE497508T1 (de) 2004-10-01 2011-02-15 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
US7892540B2 (en) 2004-10-06 2011-02-22 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
AU2005306997B2 (en) 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
CN103169965A (zh) 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
PT2028193E (pt) 2005-01-05 2012-06-15 Star Biotech Forschung Entw Gmbh Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
US8088579B2 (en) 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
AU2006216291B2 (en) 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
JP2008531719A (ja) 2005-03-02 2008-08-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｈ２介在性状態の治療のためのＫＩＭ−１抗体
WO2006099141A2 (en) 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
JP2008532559A (ja) 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP2526957A3 (de) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation von MUC1-ausdrückenden Zellen
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
KR20140068234A (ko) 2005-03-31 2014-06-05 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
PL2645106T3 (pl) 2005-04-04 2017-11-30 Biogen Ma Inc. Sposoby oceniania odpowiedzi immunologicznej na środek leczniczy
CA2607455A1 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
EP1885396A2 (de) 2005-05-04 2008-02-13 Quark Pharmaceuticals, Inc. Rekombinante antikörper gegen cd55 und cd59 und ihre verwendungen
KR101562549B1 (ko) 2005-05-10 2015-10-23 인사이트 홀딩스 코포레이션 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
AU2006247039B2 (en) 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
AU2006249835B2 (en) 2005-05-26 2011-09-08 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
UA96416C2 (uk) 2005-05-27 2011-11-10 Байоджэн Айдэк Ма Инк. Антитіло, яке зв'язується з tweak людини
EP2364998A1 (de) 2005-06-16 2011-09-14 The Feinstein Institute for Medical Research Antikörper gegen HMGB1 und Fragmente davon
WO2006138739A2 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
ES2569917T3 (es) * 2005-06-21 2016-05-13 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2006272750B2 (en) 2005-07-22 2011-09-29 Cytodyn, Inc. Methods for reducing viral load in HIV-1-infected patients
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
CN101313216A (zh) 2005-09-22 2008-11-26 普洛茨股份有限公司 酵母突变体中产生的糖基化多肽及其使用方法
EP1946768A4 (de) 2005-10-28 2009-11-11 Meiji Seika Kaisha Aussenmantel-protein pa5158 von pseudomonas aeruginosa
WO2007051077A2 (en) 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
RS53055B (en) 2005-11-01 2014-04-30 Abbvie Biotechnology Ltd PROCEDURES FOR DETERMINING THE EFFICIENCY OF ADALIMUMAB IN RESPONDENTS WHO HAVE ANKILLOSATIVE SPONDILITIS USING CTX-II AND MMP3 AS BIOMARKERS
CA2627446A1 (en) 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
EP2272497B1 (de) 2006-01-18 2012-10-03 The General Hospital Corporation Verfahren zur Erhöhung der Lymphfunktion
JP2009531295A (ja) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
EP1996622A2 (de) 2006-03-10 2008-12-03 Zymogenetics, Inc. Il-17a- und il-17f-bindende antikörper und verfahren zu ihrer anwendung
US9315578B2 (en) 2006-03-23 2016-04-19 Tohoku Univeristy High functional bispecific antibody
SG170804A1 (en) 2006-03-30 2011-05-30 Meiji Seika Kaisha Pseudomonas aeruginosa outer membrane protein pa0427
EP2004689A4 (de) 2006-04-05 2010-06-02 Abbott Biotech Ltd Antikörperreinigung
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
EP2666478A3 (de) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Schuppenflechte
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
RU2429016C2 (ru) 2006-05-31 2011-09-20 Астеллас Фарма Инк. Гуманизированное антитело против остеопонтина человека
JP2009538924A (ja) 2006-06-01 2009-11-12 エラン ファーマシューティカルズ，インコーポレイテッド Ａｐｐの神経活性断片
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
KR101396797B1 (ko) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2059531A1 (de) 2006-07-07 2009-05-20 Intercell AG Kleine streptococcus-pyogenes-antigene und anwendung davon
EP2078732B1 (de) 2006-07-10 2015-09-16 Fujita Health University Verfahren zur Identifikation möglicher diagnostischer oder therapeutischer Antikörper mittels Durchflusszytometrie
EP2046374A4 (de) 2006-07-10 2010-05-05 Biogen Idec Inc Zusammensetzungen und verfahren zur wachstumshemmung von smad4-defizienten tumoren
ES2452067T3 (es) 2006-08-04 2014-03-31 Novartis Ag Anticuerpo específico para EPHB3 y usos del mismo
US9415111B2 (en) 2006-08-11 2016-08-16 Rutgers, The State University Of New Jersey Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof
EA201201533A1 (ru) 2006-08-18 2014-11-28 Новартис Аг Prlr-специфическое антитело и его применения
EP2500416A1 (de) 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
WO2008052796A1 (en) 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
CN103073641B (zh) 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
AU2007321817A1 (en) 2006-11-17 2008-05-22 Novartis Ag Lingo binding molecules and pharmaceutical use thereof
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
US8288110B2 (en) 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
CA2672120A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonistic antibodies against ephb3
EP2102366A4 (de) 2006-12-10 2010-01-27 Dyadic International Inc Expression und hochdurchsatz-screening komplexer exprimierter dna-bibliotheken bei fadenpilzen
WO2008083169A2 (en) 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
AU2007339762B2 (en) 2006-12-27 2011-03-31 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2008083331A2 (en) 2006-12-29 2008-07-10 The Regents Of The University Of Colorado Diagnostic and therapeutic target for autoimmune diseases and uses thereof
CA2764852C (en) 2007-01-05 2018-09-18 University Of Zurich Method of providing disease-specific binding molecules and targets
WO2008084072A2 (en) 2007-01-12 2008-07-17 Intercell Ag Protective proteins of s. agalactiae, combinations thereof and methods of using the same
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
SI2130044T1 (sl) 2007-02-16 2017-03-31 Genzyme Corporation Postopek prepoznavanja tveganja motnje ščitnice
PT3067066T (pt) 2007-02-23 2019-06-17 Univ California Prevenção e tratamento da doença sinucleinopática e amiloidogénica
CN101663047B (zh) 2007-02-23 2014-07-09 纽约哥伦比亚大学理事会 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
PT2457928T (pt) 2007-03-13 2017-08-17 Univ Zuerich Anticorpo monoclonal humano específico de tumores
CA2681530C (en) 2007-03-22 2017-03-28 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154
BRPI0809665B8 (pt) 2007-04-05 2021-05-25 Eisai Inc anticorpo monoclonal que se liga especificamente a endosialina
WO2008134659A2 (en) 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2360177A1 (de) 2007-05-02 2011-08-24 Intercell AG Klebsiella-Antigene
WO2008143797A1 (en) 2007-05-11 2008-11-27 Genzyme Corporation Methods of producing a secreted protein
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
TWI614028B (zh) 2007-06-14 2018-02-11 百健Ｍａ公司 抗體調配物
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
US8921279B2 (en) 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
WO2009001940A1 (ja) 2007-06-27 2008-12-31 Asubio Pharma Co., Ltd. ペリオスチンのＥｘｏｎ－１７部位によりコードされるペプチドに対する抗体を含む癌治療剤
EP2014681A1 (de) 2007-07-12 2009-01-14 Pierre Fabre Medicament Neue Antikörper zur Hemmung der C-Met-Dimerisation und Verwendungen davon
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
AU2008293885A1 (en) 2007-07-13 2009-03-05 The John Hopkins University B7-DC variants
JP5312459B2 (ja) 2007-08-02 2013-10-09 ジリード バイオロジクス，インク． Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用
MY150621A (en) 2007-08-30 2014-02-14 Daiichi Sankyo Co Ltd Anti-epha2 antibody
JPWO2009031230A1 (ja) * 2007-09-06 2010-12-09 国立大学法人大阪大学 抗ｃｄ２０モノクローナル抗体
WO2009033071A2 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
EP2185592B1 (de) 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoklonaler amyloid-beta (abeta)-spezifischer antikörper und seine verwendung
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
PL2206727T3 (pl) 2007-10-11 2015-08-31 Daiichi Sankyo Co Ltd Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2008312802A1 (en) 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to abeta oligomer, and use thereof
CA2866649A1 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
JP2011514881A (ja) 2007-11-09 2011-05-12 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ 免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用
AU2008323206B2 (en) 2007-11-12 2014-08-14 U3 Pharma Gmbh AXL antibodies
EP2463362B1 (de) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Adenovirus SAdV-31 der Affen-Unterfamilie C und Verwendungen davon
CA2706258C (en) 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
WO2009079242A2 (en) 2007-12-05 2009-06-25 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
US8779088B2 (en) 2007-12-17 2014-07-15 Marfl Ab Vaccine for the treatment of Mycobacterium related disorders
WO2009081955A1 (ja) 2007-12-25 2009-07-02 Meiji Seika Kaisha, Ltd. 緑膿菌のiii型分泌装置構成タンパク質pa1698
EP2730659A3 (de) 2007-12-28 2016-01-13 Prothena Biosciences Limited Behandlung und Prophylaxe von Amyloidose
CA2711882C (en) 2008-01-11 2016-07-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Improved humanized anti-human .alpha.9-integrin antibody
JP2011509650A (ja) 2008-01-11 2011-03-31 株式会社ジーンテクノサイエンス ヒト化抗−α９インテグリン抗体及びその使用
BRPI0906492A2 (pt) 2008-01-11 2015-12-01 Synovex Corp antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
SG190627A1 (en) 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
JP5597553B2 (ja) 2008-03-13 2014-10-01 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
RU2540013C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
ES2527521T3 (es) 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
BRPI0909664A2 (pt) 2008-03-17 2019-09-24 Intercell Ag peptídios protetores contra s. pneumoniae e composições, métodos e usos relacionados com os mesmos
EP2268313A2 (de) 2008-03-17 2011-01-05 Universitätsklinikum Münster Yopm als abgabevehikel für cargo-moleküle und als biologische therapeutika zur immunmodulation von entzündungsreaktionen
US20110028697A1 (en) 2008-03-27 2011-02-03 Takara Bio Inc. Prophylactic/therapeutic agent for infectious disease
MY159553A (en) 2008-04-11 2017-01-13 Seattle Genetics Inc Detection and treatment of pancreatic, ovarian and other cancers
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
KR20110038047A (ko) 2008-06-20 2011-04-13 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 산화 ＬＤＬ／β２ＧＰＩ복합체에 대한 항체 및 그 용도
TR201808591T4 (tr) 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
BRPI0914319B8 (pt) 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
ES2890405T3 (es) 2008-06-25 2022-01-19 Novartis Ag Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal
PE20110308A1 (es) 2008-07-08 2011-06-10 Incyte Corp 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
WO2010008051A1 (ja) 2008-07-16 2010-01-21 株式会社医学生物学研究所 抗ヒトclcp1抗体とその用途
US9102734B2 (en) 2009-03-10 2015-08-11 Baylor Research Institute Fusion proteins comprising antibody and HPV E6 and E7 antigens
WO2010013498A1 (ja) 2008-08-01 2010-02-04 学校法人聖マリアンナ医科大学 変形性関節症治療剤又は予防剤
US8795981B2 (en) 2008-08-08 2014-08-05 Molecular Devices, Llc Cell detection
US8417011B2 (en) 2008-09-18 2013-04-09 Molecular Devices (New Milton) Ltd. Colony detection
EP2172485A1 (de) 2008-10-01 2010-04-07 Pierre Fabre Medicament Neuartige Anti-CXCR4-Antikörper und ihre Verwendung bei der Krebsbehandlung
US8715654B2 (en) 2008-10-02 2014-05-06 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
JP2012505636A (ja) 2008-10-09 2012-03-08 ミネルバ バイオテクノロジーズ コーポレーション 細胞において多能性を誘導する方法
DK2346904T3 (en) 2008-10-29 2017-06-12 China Synthetic Rubber Corp METHODS AND METHODS OF DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOM
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2774985B1 (de) 2008-10-31 2016-12-14 The Trustees Of The University Of Pennsylvania Simian-Adenovirus SAdV-43 und seine Verwendungen
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
SI2370466T1 (sl) 2008-12-19 2015-11-30 Biogen International Neuroscience Gmbh Človeška avtoprotitelesa proti alfa-sinukleinu
US8313915B2 (en) 2009-01-21 2012-11-20 Gundersen Lutheran Medical Foundation, Inc. Early detection of canine lyme disease by specific peptides and antibodies
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
WO2010089340A2 (en) 2009-02-05 2010-08-12 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
WO2010096658A1 (en) 2009-02-19 2010-08-26 The Cleveland Clinic Foundation Corin as a marker for heart failure
PT2406286T (pt) 2009-03-10 2016-08-19 Baylor Res Inst Anticorpos anti-cd40 e seus usos
MX2011009439A (es) 2009-03-10 2013-06-18 Baylor Res Inst Vacunas con especificidad de objetivo hacia celula presentadora de antigeno.
JP5725508B2 (ja) 2009-03-25 2015-05-27 国立大学法人東北大学 Ｌｈ型二重特異性抗体
JP5653909B2 (ja) 2009-04-09 2015-01-14 第一三共株式会社 抗Ｓｉｇｌｅｃ−１５抗体
CA2758322C (en) 2009-04-10 2019-04-02 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
US9090679B2 (en) 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
WO2012055980A1 (en) 2010-10-27 2012-05-03 Pierre Fabre Medicament Antibodies for the treatment of hiv
EP2246364A1 (de) 2009-04-29 2010-11-03 Pierre Fabre Médicament Antikörper gegen CXCR4 zur Behandlung von HIV
WO2010127146A1 (en) 2009-04-29 2010-11-04 Abbott Biotechnology Ltd Automatic injection device
EP2270053A1 (de) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
EP2260864A1 (de) 2009-06-10 2010-12-15 University of Melbourne Therapeutische Anwendungen
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
CA2768330A1 (en) 2009-07-28 2011-02-03 F. Hoffmann-La Roche Ag Non-invasive in vivo optical imaging method
CA2770237A1 (en) 2009-08-05 2011-02-10 Nexigen Gmbh Human hcv-interacting proteins and methods of use
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
AU2010286361A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
EP2477647B1 (de) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation von immuntherapeutischen produkten auf hefebasis und reaktionen
EP2305285A1 (de) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2308897A1 (de) 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
JP2013507618A (ja) 2009-10-11 2013-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｖｌａ‐４関連アッセイ
US8921525B2 (en) 2009-11-18 2014-12-30 Tohoku University Highly-functional mutant of humanized anti-EGFR antibody variable region
EP2332929A1 (de) 2009-11-25 2011-06-15 ArisGen SA Orthoester-Derivate aus Kronenäthern als Träger für diagnostische und pharmazeutische Zusammensetzungen
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011068870A2 (en) 2009-12-01 2011-06-09 President And Fellows Of Harvard College Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
JP2013514388A (ja) 2009-12-16 2013-04-25 フィリップ ボッシュ， 間質性膀胱炎の処置の方法
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
US9023997B2 (en) 2010-01-20 2015-05-05 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
CN102821786B (zh) 2010-01-29 2016-01-13 阿克西斯股份有限公司 含有骨关节炎治疗剂的注射液
RU2012132241A (ru) 2010-01-29 2014-03-10 Аксис, Инк. Фармацевтическая композиция для лечения или профилактики остеоартрита и способ ее производства
JP2012246222A (ja) 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
EP2531613A2 (de) 2010-02-02 2012-12-12 Abbott Biotechnology Ltd. Verfahren und zusammensetzungen zur prognose des ansprechens auf eine behandlung mit einem tnf-alpha-hemmer
MX2012008884A (es) 2010-02-08 2012-08-31 Agensys Inc Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b.
RU2565539C2 (ru) 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
KR101831459B1 (ko) * 2010-03-03 2018-04-04 더 유니버시티 오브 브리티시 콜롬비아 올리고머 특이적 아밀로이드 베타 에피토프 및 항체
EP2553449A2 (de) 2010-03-26 2013-02-06 Westfälische Wilhelms-Universität Münster Ersatztherapie für glucocorticoide
EP2371863A1 (de) 2010-03-30 2011-10-05 Pierre Fabre Médicament Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
CN103154027B (zh) 2010-04-09 2016-06-29 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
PL3202789T3 (pl) 2010-04-16 2020-09-21 Biogen Ma Inc. Przeciwciała anty-vla-4
ES2727275T3 (es) 2010-04-21 2019-10-15 Abbvie Biotechnology Ltd Dispositivo automático de inyección portátil para la liberación controlada de agentes terapéuticos
MX2012012736A (es) 2010-05-07 2013-02-26 Hoffmann La Roche Metodo de diagnostico para la deteccion de celulas ex vivo.
SG10201503904XA (en) 2010-05-17 2015-06-29 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
WO2012005076A1 (ja) 2010-07-08 2012-01-12 本田技研工業株式会社 高周波加熱用コイル
WO2012009442A2 (en) 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
LT2593128T (lt) 2010-07-15 2018-06-25 Adheron Therapeutics, Inc. Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai
CN107337735B (zh) 2010-07-29 2021-06-22 巴扎德制药公司 嵌合il-1受体i型激动剂和拮抗剂
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
CA2807244A1 (en) 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
EP2609431B1 (de) 2010-08-27 2017-05-10 University of Zurich Verfahren für target- und wirkstoffvalidierung bei entzündungs- und/oder herz-kreislauf-erkrankungen
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2623119B1 (de) 2010-09-30 2017-06-14 Riken MEDIKAMENT ZUR VERWENDUNG IN GLIOMBEHANDLUNGSVERFAHREN, GLIOMUNTERSUCHUNGSVERFAHREN, VERFAHREN ZUR ABGABE EINEr GRWÜNSCHTEN VERBINDUNG AN EIN GLIOM
US8497138B2 (en) 2010-09-30 2013-07-30 Genetix Limited Method for cell selection
ES2686550T3 (es) 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Anticuerpos anti-tau humanos
US20120093833A1 (en) 2010-10-13 2012-04-19 Juan Carlos Almagro Human Oncostatin M Antibodies and Methods of Use
US9346889B2 (en) 2010-10-18 2016-05-24 Mediapharma S.R.L. ErbB3 binding antibody
CN103561759B (zh) 2010-10-22 2016-10-12 西雅图遗传学公司 以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
ES2654820T3 (es) 2010-10-25 2018-02-15 Biogen Ma Inc. Métodos para determinar diferencias en la actividad de la alfa-4-integrina mediante la correlación de las diferencias en los niveles de sVCAM y/o sMAdCAM
NZ623347A (en) 2010-10-29 2014-07-25 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
EP2640425A2 (de) 2010-11-18 2013-09-25 Beth Israel Deaconess Medical Center, Inc. Verfahren zur behandlung von adipositas durch hemmung von nicotinamid-n-methyl-transferase (nnmt)
WO2012068540A2 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
AU2011343161B2 (en) 2010-12-17 2017-02-02 Neurimmune Holding Ag Human anti-SOD1 antibodies
WO2012090939A1 (ja) 2010-12-27 2012-07-05 国立大学法人名古屋大学 受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
DK2663580T3 (en) 2011-01-10 2017-03-13 Ct Atlantic Ltd COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
EP3187216B1 (de) 2011-01-24 2019-08-21 AbbVie Biotechnology Ltd. Automatische injektionsvorrichtungen mit umspritzten greifflächen
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012110843A1 (en) 2011-02-18 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
US20140044644A1 (en) 2011-02-21 2014-02-13 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
JP6385060B2 (ja) 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療的に活性な抗体のインビボにおける選択
EP2684045B2 (de) 2011-03-09 2023-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur charakterisierung von patienten mit hämolyse
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
KR101551555B1 (ko) 2011-03-17 2015-09-08 밀테니 비오텍 게앰베하 Tcr 알파/베타가 고갈된 세포 제제
EP2688592A4 (de) 2011-03-25 2015-07-22 Baylor Res Inst Zusammensetzungen und verfahren zur immunisierung gegen den hepatitis-c-virus
TW201249867A (en) 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
MX345747B (es) 2011-04-21 2017-02-14 Abbvie Inc Dispositivo de inyección automático portable.
PL2703486T3 (pl) 2011-04-25 2018-07-31 Daiichi Sankyo Company, Limited Przeciwciało anty-b7-h3
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012154889A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Serum s100b and uses thereof
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2530088A1 (de) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Mittel und Verfahren zur Diagnose und Behandlung von Multipler Sklerose
US20140093514A1 (en) 2011-06-03 2014-04-03 University Of Zurich Magea3 binding antibodies
JP2014524891A (ja) 2011-06-03 2014-09-25 シーティー アトランティック リミテッド Ｍａｇｅａ３結合抗体
JP6305919B2 (ja) 2011-06-06 2018-04-04 プロセナ バイオサイエンシーズ リミテッド Ｍｃａｍアンタゴニスト及び治療の方法
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
JP5376095B2 (ja) 2011-08-11 2013-12-25 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013024517A1 (ja) 2011-08-12 2013-02-21 国立感染症研究所 アスペルギルス フミガーツス感染症の検査、予防及び治療のための方法並びに組成物
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
HUE036177T2 (hu) 2011-09-19 2018-06-28 Axon Neuroscience Se TAU-mediált patológia protein alapú terápiája és diagnózisa Alzheimer-betegségben
GB2495115A (en) * 2011-09-29 2013-04-03 Oxford Plastic Sys Ltd Base for supporting temporary fence panels or posts.
TW201329105A (zh) 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
EP2764118A1 (de) 2011-10-05 2014-08-13 University of Bremen Wnt4 und med12 zur verwendung bei der diagnose und behandlung von tumorerkrankungen
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
JP6466170B2 (ja) 2011-10-17 2019-02-06 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞の増殖及び誘導用の培地
WO2013057313A1 (en) 2011-10-20 2013-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the detection and the treatment of cardiac remodeling
EP2589609A1 (de) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
EP2782933A1 (de) 2011-11-22 2014-10-01 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur verringerung von atemwegüberreaktion
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
ES2638649T3 (es) 2011-11-28 2017-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento
EP2602621A1 (de) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, neuer Harnmarker zur Erkennung eines Übergangszellenkarzinoms
BR112014014258A2 (pt) * 2011-12-13 2020-10-27 Nordic Nanovector As. molécula de anticorpo que se liga a cd37 humano; anticorpo; molécula de dna; vetor de expressão; célula hospedeira; método para produzir um anticorpo; composição farmacêutica; método de esgotamento de células b que expressam cd37 dentre uma população de células; radioimunoconjugado que se liga a cd37 humano; método de tratamento de uma malignidade de célula b; kit para a produção do radioimunoconjugado; e preparação injetável de anticorpo hh1 quimérico ou humanizado para uso no pré-tratamento de uma malignidade de célula b
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
WO2013098419A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
US20150216998A1 (en) 2012-01-01 2015-08-06 Ramot At Tel-Aviv University Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
CN108324943B (zh) 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
CN104271122A (zh) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
KR102051505B1 (ko) 2012-02-23 2019-12-03 다이이치 산쿄 유럽 게엠베하 방사선 감수성 조절을 위한 ｈｅｒ３ 억제제
US9371391B2 (en) 2012-02-28 2016-06-21 Astellas Pharma Inc. Anti-human IL-23 receptor antibody and encoding polynucleotides
SG10201710574UA (en) 2012-03-15 2018-02-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
CA2867902C (en) 2012-03-20 2023-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
TW201345925A (zh) 2012-03-30 2013-11-16 Daiichi Sankyo Co Ltd 新穎抗ｓｉｇｌｅｃ－１５抗體
TW201343672A (zh) 2012-03-30 2013-11-01 Daiichi Sankyo Co Ltd Ｃｄｒ經修飾之抗ｓｉｇｌｅｃ－１５抗體
ES2702278T3 (es) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
CA2869394A1 (en) 2012-04-02 2013-10-10 Gundersen Lutheran Health System, Inc. Reagents, methods, and kits for the classification of cancer
SG10201608382QA (en) 2012-04-09 2016-12-29 Daiichi Sankyo Co Ltd Anti-fgfr2 antibody
PL2841457T3 (pl) 2012-04-27 2019-09-30 Daiichi Sankyo Company, Limited Przeciwciało anty-ROBO4
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
JP6263117B2 (ja) 2012-05-11 2018-01-17 公益財団法人微生物化学研究会 抗ｃｘａｄｒ抗体
US9512223B2 (en) 2012-05-15 2016-12-06 Morphotek, Inc. Methods for treatment of gastric cancer
CN105473723A (zh) 2012-05-18 2016-04-06 宾夕法尼亚大学托管会 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途
US20150140010A1 (en) 2012-05-22 2015-05-21 Inserm 9Institut National De La Sante Et De La R- Echerche Medicale) Methods for diagnosing and treating focal segmental glomerulosclerosis
MX369626B (es) 2012-05-24 2019-11-13 Mountgate Group Ltd Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
LT4019041T (lt) 2012-07-13 2023-04-11 The Trustees Of The University Of Pennsylvania Toksiškumo, atsirandančio dėl car receptorių priešnavikinio aktyvumo, suvaldymas
EP2875049B1 (de) 2012-07-18 2018-12-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zur vorbeugung und behandlung chronische niereninsuffizienz (ckd)
CN104582717B (zh) 2012-07-19 2018-03-13 雷德伍德生物科技股份有限公司 对cd22有特异性的抗体及其使用方法
AU2013297478B2 (en) 2012-07-30 2018-12-20 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody against human midkine
EP3838923B1 (de) 2012-08-24 2024-05-01 The Regents of The University of California Antikörper und impfstoffe zur verwendung in der behandlung von ror1-krebsarten und zur hemmung von metastasen
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
WO2014042251A1 (ja) 2012-09-13 2014-03-20 中外製薬株式会社 遺伝子ノックイン非ヒト動物
EP2711016A1 (de) 2012-09-21 2014-03-26 Covagen AG Neue IL-17A-Verbindungsmoleküle und medizinische Verwendungen davon
RS57120B1 (sr) 2012-10-03 2018-06-29 Chiome Bioscience Inc Anti-humano dlk-1 antitelo koje ima in vivo aktivnost protiv tumora
EP3677310A1 (de) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapien auf der basis der steuerung der stabilität und funktion regulatorischer t-zellen über eine neuropilin-1:semaphorin-achse
WO2014057687A1 (ja) 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
JP6272230B2 (ja) 2012-10-19 2018-01-31 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
EP3508503B1 (de) 2012-11-01 2022-11-02 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Antikörper gegen cd269 (bcma)
AR093357A1 (es) 2012-11-05 2015-06-03 Pf Medicament Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
WO2014072416A1 (en) 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bone metastases
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
RS60084B1 (sr) 2012-12-10 2020-05-29 Biogen Ma Inc Antitela anti-antigen 2 dendritske ćelije krvi i njihove upotrebe
US20160185847A1 (en) 2012-12-17 2016-06-30 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
WO2014100602A1 (en) 2012-12-20 2014-06-26 Hospital For Special Surgery Treatment of egf-receptor dependent pathologies
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
EP2938631B1 (de) 2012-12-31 2018-12-19 Neurimmune Holding AG Rekombinante menschliche antikörper zur therapie und vorbeugung von erkrankungen im zusammenhang mit polyomavirus
EP2752426A1 (de) 2013-01-03 2014-07-09 Covagen AG Humane Serumalbumin bindende Verbindungen und Fusionsproteine daraus
SI2949675T1 (sl) 2013-01-28 2021-08-31 Evec Inc. Humanizirano protitelo ANTI-HMGB1 ali njegov antigen-vezavni fragment
EP2951589A1 (de) 2013-02-01 2015-12-09 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren zur vorhersage und vorbeugung von metastasen in dreifach negativen brustkrebsen
JP6357113B2 (ja) 2013-02-08 2018-07-11 株式会社医学生物学研究所 ヒトｎｒｇ１タンパク質に対する抗体
EP2956478A1 (de) 2013-02-15 2015-12-23 ESBATech - a Novartis Company LLC Akzeptorrahmen für pcdr-fropfung
CN104884471A (zh) 2013-02-20 2015-09-02 艾斯巴技术-诺华有限责任公司 用于cdr移植的受体框架
FR3004184B1 (fr) 2013-02-26 2016-03-18 Agronomique Inst Nat Rech Anticorps anti-gluten desamide et utilisations.
JP6490574B2 (ja) 2013-02-28 2019-03-27 国立研究開発法人国立がん研究センター 不溶性フィブリンに対する抗体
JP6218088B2 (ja) 2013-03-08 2017-11-01 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ−２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
BR112015022587A2 (pt) 2013-03-13 2017-10-24 Eleven Biotherapeutics Inc formulações de citocina quimérica para entrega ocular
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EP2968550B1 (de) 2013-03-14 2018-11-14 Ffe Therapeutics LLC Zusammensetzungen und verfahren zur behandlung von angiogenesebedingten erkrankungen
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
KR20150128796A (ko) 2013-03-15 2015-11-18 바이오젠 엠에이 인코포레이티드 항-알파 v 베타 5개 항체를 이용한 급성 신장 손상의 치료 및 예방
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2014165524A2 (en) 2013-04-01 2014-10-09 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb8 integrin
WO2014174596A1 (ja) 2013-04-23 2014-10-30 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN107460201A (zh) 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
EP3159695A3 (de) 2013-06-20 2017-07-05 The Trustees of The University of Pennsylvania Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2015001013A2 (en) 2013-07-03 2015-01-08 Immunoqure Ag Human anti-ifn-alpha antibodies
US20160176943A1 (en) 2013-07-05 2016-06-23 Inserm (Insititut National De La Sante Et De La Recherche Medicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
WO2015003114A1 (en) 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
JP6380394B2 (ja) 2013-08-09 2018-08-29 アステラス製薬株式会社 新規抗ヒトｔｓｌｐ受容体抗体
WO2015036956A1 (en) 2013-09-12 2015-03-19 Institut National De La Sante Et De La Recherche Medicale Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
AU2014322988B2 (en) 2013-09-20 2018-12-06 Westfaelische Wilhelms-Universitaet Muenster Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
CN105764923A (zh) 2013-09-24 2016-07-13 范因斯坦医学研究院 对可冷诱导的rna结合蛋白活性进行抑制的肽
WO2015048531A1 (en) 2013-09-26 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Inhibition of sgk1 in the treatment of heart conditions
EP3835422A1 (de) 2013-09-30 2021-06-16 Daiichi Sankyo Company, Limited Anti-lps-o11-antikörper
EP3052131B1 (de) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Verfahren zur krebsbehandlung bei patienten mit erhöhtem bim-spiegel
JP6509735B2 (ja) 2013-10-08 2019-05-08 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
JPWO2015068781A1 (ja) 2013-11-06 2017-03-09 国立大学法人大阪大学 インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
EP3466445A1 (de) 2013-11-06 2019-04-10 Janssen Biotech, Inc. Anti-ccl17-antikörper
WO2015071701A1 (en) 2013-11-15 2015-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pancreatic cancers
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
CN105829534B (zh) 2013-12-24 2021-08-03 安斯泰来制药株式会社 抗人bdca-2抗体
CA2933666C (en) 2013-12-25 2021-08-03 Sapporo Medical University Anti-trop2 antibody-drug conjugate
ES2902835T3 (es) 2014-01-09 2022-03-30 Hadasit Med Res Service Composiciones celulares mejoradas y métodos para la terapia contra el cáncer
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
KR102362920B1 (ko) 2014-01-31 2022-02-14 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
WO2015124588A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
EP2915543B1 (de) 2014-03-04 2018-05-09 Albert-Ludwigs-Universität Freiburg Aus Enterococcus abgeleitete Polypeptide und Verwendung davon zur Impfung und Erstellung von therapeutischen Antikörpern
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
SG11201608309PA (en) 2014-04-10 2016-11-29 Daiichi Sankyo Co Ltd Anti-her3 antibody-drug conjugate
EP3134546A4 (de) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumorsuppressor und onkogene biomarker zur vorhersage der anti-immun-checkpoint-inhibitorreaktion
PL3134124T3 (pl) 2014-04-25 2019-09-30 Pierre Fabre Medicament Koniugat przeciwciało IGF-IR-lek i jego zastosowanie do leczenia raka
CA2946796C (en) 2014-04-25 2019-10-22 Pierre Fabre Medicament Antibody-drug-conjugate and its use for the treatment of cancer
EP3783033A1 (de) 2014-04-25 2021-02-24 Pierre Fabre Medicament Igf-1r-antikörper und dessen verwendung als adressierungsmedium zur behandlung von krebs
MD20160130A2 (ro) 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Anticorpi umanizaţi contra CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3160493A4 (de) 2014-06-26 2018-04-11 Yale University Zusammensetzungen und verfahren zur renalaseregulierung bei der behandlung von erkrankungen und störungen
CN112979828A (zh) 2014-07-17 2021-06-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
EP3169691B1 (de) 2014-07-17 2020-09-02 The Trustees Of The University Of Pennsylvania Verfahren zur verwendung von exosomen zur überwachung des zustands eines transplantierten organs
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
KR102594327B1 (ko) 2014-09-30 2023-10-27 뉴리뮨 홀딩 아게 인간-유래의 항-디펩티드 반복체(dpr) 항체
EP3201226A2 (de) 2014-10-03 2017-08-09 Massachusetts Institute of Technology Antikörper zur bindung von ebola-glycoprotein und verwendungen davon
CA2963091A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP6941561B2 (ja) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
ES2832802T3 (es) 2014-11-21 2021-06-11 Univ Maryland Sistemas de administración dirigida del particulado específico de una estructura
WO2016087889A1 (en) 2014-12-03 2016-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
AU2016229238B2 (en) 2015-03-06 2022-06-02 Dana-Farber Cancer Institute, Inc. PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
EP3067062A1 (de) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Kombination von tasquinimod oder einem pharmazeutisch zulässigen salz davon und pd1 und/oder pdl1-hemmer zur verwendung als medikament
US20180092977A1 (en) 2015-03-18 2018-04-05 The Johns Hopkins University Novel monoclonal antibody inhibitors targeting potassium channel kcnk9
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
US10214591B1 (en) 2015-04-03 2019-02-26 Alienor Farma Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
ES2841437T3 (es) 2015-04-13 2021-07-08 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas
JP2018519248A (ja) 2015-04-22 2018-07-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔｈ１７媒介性疾患の処置のための方法及び医薬組成物
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
JP2018517712A (ja) 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体特異的抗体
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
CN107922457B (zh) 2015-06-19 2022-05-13 森托瑞恩生物制药公司 用于控制药物释放的递送系统
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
CA2994825A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
WO2017046335A1 (en) 2015-09-18 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
DK3353196T3 (da) 2015-09-22 2023-02-20 Inst Nat Sante Rech Med Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
AU2016325858B2 (en) 2015-09-24 2022-05-26 Daiichi Sankyo Company, Limited Anti-GARP antibody
WO2017059196A2 (en) 2015-09-30 2017-04-06 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use
JP6857360B2 (ja) 2015-10-08 2021-04-14 国立大学法人東海国立大学機構 キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
WO2017064716A1 (en) 2015-10-13 2017-04-20 Rappaport Family Institute For Research Heparanase-neutralizing monoclonal antibodies
EP3362082A1 (de) 2015-10-16 2018-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung entzündlicher augenkrankheiten
MX2018005070A (es) 2015-10-26 2018-09-06 Pf Medicament Composición para el tratamiento de cáncer con expresión del igf-1r.
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
ITUB20155272A1 (it) 2015-11-02 2017-05-02 Scuola Normale Superiore Intracellular antibody
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
ITUB20155097A1 (it) 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
US10829562B2 (en) 2015-12-10 2020-11-10 Katholieke Universiteit Leuven Haemorrhagic disorder due to ventricular assist device
BR112018012344A2 (pt) 2015-12-17 2018-12-04 Janssen Biotech Inc anticorpos que se ligam especificamente a hla-dr e seus usos
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
KR20200100858A (ko) 2015-12-23 2020-08-26 메디진 이뮤노테라피스 게엠바하 수지상 세포 조성물
KR102430893B1 (ko) 2015-12-31 2022-08-09 프로가스트린 에 캔서스 에스.에이 알.엘. 식도암을 검출 및 치료하기 위한 조성물 및 방법
WO2017114975A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating gastric cancer
AU2017204682B2 (en) 2015-12-31 2021-07-29 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
EP3202788A1 (de) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialinbindender antikörper
EP3205663A1 (de) 2016-02-15 2017-08-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mittel und verfahren zur hemmung der genexpression
WO2017140684A2 (en) 2016-02-15 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
US10906987B2 (en) 2016-03-01 2021-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (PVR)
WO2017153432A1 (en) 2016-03-07 2017-09-14 Pierre Fabre Medicament A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
WO2017156263A1 (en) 2016-03-09 2017-09-14 Memorial Sloan-Kettering Cancer Center Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
KR102408161B1 (ko) 2016-03-15 2022-06-13 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3433615A1 (de) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zur diagnose und behandlung von sonnenpigmentflecken
CA3007135A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
SI3436461T1 (sl) 2016-03-28 2024-03-29 Incyte Corporation Pirolotriazinske spojine kot tam-inhibitorji
ITUA20162242A1 (it) 2016-04-01 2017-10-01 St Biochimico Italiano Giovanni Lorenzini Spa Un nuovo anticorpo anti-erbb2
LT3445785T (lt) 2016-04-18 2022-10-10 Faron Pharmaceuticals Oy Humanizuoti anti clever-1 antikūnai ir jų naudojimas
EP3452512B1 (de) 2016-05-03 2023-03-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von gewebeläsionen
CN109219660B (zh) 2016-05-11 2023-01-06 美国安进公司 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞
JP2019516799A (ja) 2016-05-20 2019-06-20 カール、クリストフＫＡＲＬ， Ｃｈｒｉｓｔｏｐｈ 骨代謝の障害および低カルシウム血症などの治療誘発性副作用の処置および／または予防に適した、抗ｒａｎｋｌ抗体、カルシウムおよびビタミンｄを含む薬学的組成物
WO2017202814A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
AU2017276706A1 (en) 2016-06-07 2019-01-03 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
ES2883182T3 (es) 2016-07-06 2021-12-07 Prothena Biosciences Ltd Ensayo para la detección de alfa-sinucleína total y fosforilada en S129
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
US20190271702A1 (en) 2016-07-28 2019-09-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of treatement of cancer disease by targetting tumor associated macrophage
EP3497126A4 (de) 2016-08-12 2020-04-08 Janssen Biotech, Inc. Fc-manipulierte antikörper der anti-tnfr-superfamilie mit erhöhter agonistischer aktivität und verfahren zur verwendung davon
KR102587941B1 (ko) 2016-08-12 2023-10-11 얀센 바이오테크 인코포레이티드 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
AU2017332721B2 (en) 2016-09-20 2023-11-09 Sara BUHRLAGE Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
JPWO2018066626A1 (ja) 2016-10-07 2019-07-18 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療
EP3527225A4 (de) 2016-10-12 2020-06-10 Daiichi Sankyo Company, Limited Zusammensetzung mit anti-robo4-antikörper und anderen mitteln
CU20190036A7 (es) 2016-10-13 2019-11-04 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika
IT201600111877A1 (it) 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
CN110049779A (zh) 2016-12-12 2019-07-23 第一三共株式会社 抗体-药物缀合物和免疫检查点抑制剂的组合
EP3556773A4 (de) 2016-12-13 2020-08-19 Astellas Pharma Inc. Antikörper gegen menschliches cd73
JP2020514256A (ja) 2016-12-15 2020-05-21 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 抗ｐｃｎａモノクローナル抗体及びその使用
CA3048174A1 (en) 2016-12-22 2018-06-28 Daiichi Sankyo Company, Limited Anti-cd3 antibody and molecules comprising the antibody
US20180179490A1 (en) 2016-12-27 2018-06-28 Miltenyi Biotec Gmbh CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
WO2018129284A1 (en) 2017-01-05 2018-07-12 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
CA3050668C (en) 2017-01-17 2023-08-15 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
AU2018218753A1 (en) 2017-02-07 2019-09-26 Daiichi Sankyo Company, Limited Anti-GPRC5D antibody and molecule containing same
EP3363459A1 (de) 2017-02-17 2018-08-22 Alexander Klimka Polypeptid-epitope von s. aureus und entsprechende monoklonale antikörper zur behandlung von infektionen und immundiagnose
US11623953B2 (en) 2017-02-27 2023-04-11 Caerus Therapeutics, Inc. Antibody constructs and methods of treating cancer
JP7181181B2 (ja) 2017-02-28 2022-11-30 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法
CN110753702B (zh) 2017-03-15 2022-09-20 清华大学 抗trkb抗体
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
CA3058263C (en) 2017-03-30 2023-08-01 Ecs-Progastrin Sa Compositions and methods for detecting prostate cancer
EP3602061B1 (de) 2017-03-30 2022-07-20 ECS-Progastrin SA Zusammensetzungen und verfahren zum nachweis von lungenkrebs
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
CN111201034A (zh) 2017-05-11 2020-05-26 西托戴恩股份有限公司 涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CA3065516A1 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
WO2019005503A1 (en) 2017-06-29 2019-01-03 Rutgers, The State University Of New Jersey COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY
CN110913905A (zh) 2017-06-30 2020-03-24 国立大学法人北海道大学 不产生生长障碍的小儿骨质疏松症治疗药
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
EP3655031A1 (de) 2017-07-21 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Immunogene zusammensetzungen gegen neisseria meningitidis
TW202402805A (zh) 2017-07-27 2024-01-16 日商第一三共股份有限公司 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
EP3658582A1 (de) 2017-07-28 2020-06-03 Intrepida Bio, Inc. Anti-bag3-antikörper als therapeutisches reagenz bei kardiovaskulären erkrankungen
WO2019025299A1 (en) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag METHOD OF HUMANIZATION BASED ON THREE DIMENSIONAL STRUCTURE
EP3444272A1 (de) 2017-08-17 2019-02-20 International-Drug-Development-Biotech Behandlung von ck8-positivem krebs in verbindung mit dem k-ras-genstatus
KR20200039783A (ko) 2017-08-23 2020-04-16 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
BR112020003474A2 (pt) 2017-08-23 2020-10-20 Daiichi Sankyo Company, Limited composição farmacêutica, e, método para produzir uma composição farmacêutica
KR20200041993A (ko) 2017-08-31 2020-04-22 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
IL272964B2 (en) 2017-08-31 2024-02-01 Daiichi Sankyo Co Ltd Production method for antibody-drug conjugates
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
US20200345800A1 (en) 2017-10-03 2020-11-05 Tokyo Metropolitan Institute Of Medical Science Medication for influenza
CN111447952A (zh) 2017-10-05 2020-07-24 第一三共株式会社 用于细胞毒性t细胞耗竭的组合物
KR101966362B1 (ko) 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
IL305268A (en) 2017-11-30 2023-10-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems
EP3717503B1 (de) 2017-11-30 2023-11-08 LadRx Corporation Albuminbindende prodrugs von auristatin-e-derivaten
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
PT3720879T (pt) 2017-12-05 2022-07-13 Progastrine Et Cancers S A R L Terapia de combinação entre anticorpo anti-progastrina e imunoterapia para tratar o cancro
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
US20190225689A1 (en) 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
WO2019145537A1 (en) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
EP3752252A4 (de) 2018-02-12 2021-11-17 Hadasit Medical Research Services and Development Ltd. Modulation von slamf6-spleissvarianten für die krebstherapie
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
EP3759492A1 (de) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin als biomarker für immuntherapie
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
JP7125979B2 (ja) 2018-03-05 2022-08-25 学校法人 埼玉医科大学 異所性骨化の治療又は予防のための医薬組成物
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
EP3775908A1 (de) 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage des ergebnisses und der behandlung von patienten mit prostatakrebs oder brustkrebs
WO2019201995A1 (en) 2018-04-20 2019-10-24 Medizinische Hochschule Hannover Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
WO2019207066A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of sjögren's syndrome
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
JP2021522801A (ja) 2018-05-09 2021-09-02 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトネクチン４に特異的な抗体
BR112020023041A2 (pt) 2018-05-11 2021-02-09 Astellas Pharma Inc. ácido nucleico para tratar alergia a ácaros
BR112020023031A2 (pt) 2018-05-11 2021-02-09 Astellas Pharma Inc. ácido nucleico para tratar alergia a crustáceo
JP7360766B2 (ja) 2018-05-17 2023-10-13 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
EA202092847A1 (ru) 2018-05-24 2021-04-20 Янссен Байотек, Инк. Антитела к cd3 и их применение
BR112020024061A2 (pt) 2018-05-28 2021-02-17 Daiichi Sankyo Company, Limited agente terapêutico para câncer com her2 mutado
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP6790307B2 (ja) 2018-05-31 2020-11-25 第一三共株式会社 抗ヒトｔｌｒ７抗体
KR20210016390A (ko) 2018-06-01 2021-02-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
KR20210030366A (ko) 2018-06-20 2021-03-17 인사이트 코포레이션 항-pd-1 항체 및 이의 용도
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
CN117771250A (zh) 2018-06-29 2024-03-29 因赛特公司 Axl/mer抑制剂的制剂
WO2020007898A1 (en) 2018-07-04 2020-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating brain injury or neurodegenerative disease
KR20210038904A (ko) 2018-07-25 2021-04-08 다이이찌 산쿄 가부시키가이샤 항체-약물 콘쥬게이트의 효과적인 제조 방법
KR20210040059A (ko) 2018-07-27 2021-04-12 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 약물 부위를 인식하는 단백질
WO2020022499A1 (ja) 2018-07-27 2020-01-30 国立大学法人大阪大学 老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
JP7458981B2 (ja) 2018-08-06 2024-04-01 第一三共株式会社 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
CN112714649A (zh) 2018-09-06 2021-04-27 第一三共株式会社 新型环状二核苷酸衍生物及其抗体药物偶联物
TW202024133A (zh) 2018-09-20 2020-07-01 日商第一三共股份有限公司 利用投予抗her3抗體-藥物結合物之her3突變癌之治療
WO2020059847A1 (ja) 2018-09-21 2020-03-26 国立大学法人 東京医科歯科大学 ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
CA3113378C (en) 2018-09-27 2024-01-02 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
US20220048966A1 (en) 2018-09-28 2022-02-17 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020079164A1 (en) 2018-10-18 2020-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
JOP20210093A1 (ar) 2018-10-31 2023-01-30 Astellas Pharma Inc جسم مضاد fn14 غير متوافق مع الإنسان
EP3880706A1 (de) 2018-11-12 2021-09-22 MediaPharma S.r.l. Bispezifische antikörper gegen menschliches 90k und entweder endosialin oder her3
JP7401456B2 (ja) 2018-11-14 2023-12-19 第一三共株式会社 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
SG11202106248XA (en) 2018-12-11 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate with parp inhibitor
WO2020132560A2 (en) 2018-12-21 2020-06-25 Aim Immunotech Inc. Compositions and methods for cancer therapy
EP3903828A4 (de) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited Kombination aus antikörper-arzneimittel-konjugat und kinaseinhibitor
KR20210113202A (ko) 2019-01-07 2021-09-15 아스텔라스세이야쿠 가부시키가이샤 배위자, 스페이서, 펩티드 링커 및 생물 분자를 포함하는 복합체
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
WO2020144697A1 (en) 2019-01-13 2020-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin-2
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220125754A1 (en) 2019-01-29 2022-04-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
EP3924386A4 (de) 2019-02-13 2023-01-04 The Brigham & Women's Hospital, Inc. Anti-peripherische lymphknoten ansprechende antikörper und verwendungen davon
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
US20220154153A1 (en) 2019-03-22 2022-05-19 Université de Paris New inhibitors of lrrk2/pp1 interaction
TW202102225A (zh) 2019-03-25 2021-01-16 日商第一三共股份有限公司 抗her2抗體-吡咯并苯二氮呯衍生物結合物
TW202102228A (zh) 2019-03-25 2021-01-16 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物
US20220154191A1 (en) 2019-03-25 2022-05-19 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Enhancement of cytolytic t-cell activity by inhibiting ebag9
WO2020196712A1 (ja) 2019-03-27 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
KR20210144767A (ko) 2019-04-01 2021-11-30 치오메 바이오사이언스 가부시키가이샤 암 치료용 의약
AU2020253449A1 (en) 2019-04-02 2021-11-18 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
WO2020229546A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
US20230270870A1 (en) 2019-05-29 2023-08-31 Daiichi Sankyo Company, Limited Dosage of an antibody-drug conjugate
WO2020261093A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
UY38803A (es) 2019-07-26 2021-01-29 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas
US20220267453A1 (en) 2019-07-26 2022-08-25 Saitama Medical University Antibody recognizing extracellular region of alk2/acvr1
WO2021019706A1 (ja) 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
EP4007602A1 (de) 2019-08-01 2022-06-08 Incyte Corporation Dosierungsschema für einen ido-inhibitor
BR112022001037A2 (pt) 2019-08-02 2022-06-07 Cytodyn Inc Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5
CN114555637A (zh) 2019-08-12 2022-05-27 比昂生物制剂公司 针对ilt2的抗体及其用途
EP3792632A1 (de) 2019-09-16 2021-03-17 Vito NV Immuntherapiemarker
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
EP4034151A1 (de) 2019-09-27 2022-08-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von müllerschen hemmstoff-inhibitoren zur behandlung von krebs
EP4034160A1 (de) 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anti-ceacam-antikörper und verwendungen davon
EP4049675A4 (de) 2019-10-25 2023-11-22 Daiichi Sankyo Company, Limited Kombination von anti-garp-antikörper und immunregulator
CA3163339A1 (en) 2019-11-15 2021-05-20 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
PE20221325A1 (es) * 2019-12-10 2022-09-09 Ccoa Therapeutics Inc Anticuerpos anti-glicoproteina ib alfa humanizada (gpibalpha)
JP2023509373A (ja) 2019-12-20 2023-03-08 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
MX2022008208A (es) 2020-01-03 2022-10-21 Incyte Corp Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1).
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
US20230070181A1 (en) 2020-02-05 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of cancer disease by targeting an epigenetic factor
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
WO2021175924A1 (en) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
IL296065A (en) 2020-03-06 2022-10-01 Incyte Corp Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
MX2022009597A (es) 2020-03-06 2022-09-02 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-farmaco que incluye derivado de dinucleotido ciclico novedoso.
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
PE20230001A1 (es) 2020-03-13 2023-01-05 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33
JPWO2021200131A1 (de) 2020-03-30 2021-10-07
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
EP3889183A1 (de) 2020-04-01 2021-10-06 Pierre Fabre Medicament Proteinkomplex mit einem immunzytokin
AU2021253899A1 (en) 2020-04-06 2022-11-17 University Of Rijeka Faculty Of Medicine Antibodies to NKp46 and constructs thereof for treatment of cancers and infections
EP4151655A1 (de) 2020-05-14 2023-03-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd25-antikörper, antigenbindende fragmente davon und medizinische verwendungen davon
WO2021233962A1 (en) 2020-05-19 2021-11-25 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
CA3184189A1 (en) 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
BR112022023931A2 (pt) 2020-05-27 2023-04-11 Arialys Therapeutics Inc Derivado de anticorpo nr1 anti-humano
CN116529267A (zh) 2020-06-04 2023-08-01 肯乔克蒂生物技术股份有限公司 Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
EP4171651A1 (de) 2020-06-24 2023-05-03 AstraZeneca UK Limited Kombination aus antikörper-wirkstoff-konjugat und atm-inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
JP2023542065A (ja) 2020-06-24 2023-10-05 アストラゼネカ ユーケー リミテッド 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
CN116635082A (zh) 2020-06-24 2023-08-22 阿斯利康(英国)有限公司 抗体-药物缀合物和atr抑制剂的组合
EP4171527A1 (de) 2020-06-25 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung und diagnose pathologischer zustände in zusammenhang mit intensivem stress
TW202216212A (zh) 2020-07-17 2022-05-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
US20230293714A1 (en) 2020-07-20 2023-09-21 Daiichi Sankyo Company, Limited Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
CA3190307A1 (en) 2020-07-29 2022-02-03 Janssen Biotech, Inc. Proteins comprising hla-g antigen binding domains and their uses
RU2764216C1 (ru) * 2020-08-10 2022-01-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
IL300588A (en) 2020-08-12 2023-04-01 Biond Biologics Ltd Antibodies against ILT-2 and their use
US20240009310A1 (en) 2020-08-24 2024-01-11 Charité - Universitätsmedizin Berlin A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
EP4199958A1 (de) 2020-08-24 2023-06-28 Charité - Universitätsmedizin Berlin Chimäre antigenrezeptor(car)-exprimierende zellen zur cea-erkennung
EP4208259A2 (de) 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4-antikörper und verwendungen davon
US20230340149A1 (en) 2020-09-07 2023-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of inflammatory bowel diseases
JP2023545359A (ja) 2020-09-12 2023-10-30 アストラゼネカ・ユーケイ・リミテッド 抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法
IL301883A (en) 2020-10-05 2023-06-01 Chiome Bioscience Inc A drug to treat cancer
BR112023006337A2 (pt) 2020-10-09 2023-05-09 Astrazeneca Uk Ltd Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
UY39467A (es) 2020-10-13 2022-04-29 Janssen Biotech Inc Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
EP4232064A1 (de) 2020-10-21 2023-08-30 Institut National de la Santé et de la Recherche Médicale (INSERM) C-terminale sparc-fragmente zur behandlung von krebs
WO2022084915A1 (en) 2020-10-22 2022-04-28 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
KR20230113564A (ko) 2020-11-06 2023-07-31 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 다낭성 난소 증후군(pcos)의 진단 및 치료 방법
TW202227140A (zh) 2020-11-11 2022-07-16 日商第一三共股份有限公司 抗體-藥物結合物及抗SIRPα抗體之組合
TW202233249A (zh) 2020-11-12 2022-09-01 日商第一三共股份有限公司 藉由投與抗b7-h3抗體-藥物結合物之間皮瘤之治療
AR124063A1 (es) 2020-11-16 2023-02-08 Astellas Pharma Inc Anticuerpo biespecífico anti-tspan8 / anti-cd3 y anticuerpo anti-tspan8
WO2022112469A1 (en) 2020-11-27 2022-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring of toxic epidermal necrolysis
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
JP2023551519A (ja) 2020-11-30 2023-12-08 インサイト・コーポレイション 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法
WO2022124247A1 (ja) 2020-12-09 2022-06-16 国立大学法人 東京医科歯科大学 前頭側頭葉変性症の予防又は治療剤
EP4271384A1 (de) 2020-12-29 2023-11-08 Incyte Corporation Kombinationstherapie mit a2a/a2b-inhibitoren, pd-1/pd-l1-inhibitoren und anti-cd73-antikörpern
MX2023008261A (es) 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
US20240115721A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
AU2022219681A1 (en) 2021-02-11 2023-09-21 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
CN116848136A (zh) 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
CN117425674A (zh) 2021-03-02 2024-01-19 丹娜法伯癌症研究院 治疗红细胞疾患的方法
CN116917341A (zh) 2021-03-12 2023-10-20 第一三共株式会社 糖链以及包含糖链的医药品的制造方法
WO2022189632A1 (en) 2021-03-12 2022-09-15 Fibrosys S.R.L. Monoclonal antibodies for the treatment of viral infections
TW202304986A (zh) 2021-03-24 2023-02-01 美商健生生物科技公司 靶向cd22及cd79b的抗體
IL307168A (en) 2021-03-26 2023-11-01 Janssen Biotech Inc Humanized antibodies against paired helical strands of TAU protein and their uses
WO2022218998A1 (en) 2021-04-13 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating hepatitis b and d virus infection
JP2024513921A (ja) 2021-04-14 2024-03-27 ヴィラリス・セラピューティクス・インコーポレイテッド 抗ｃｄ１２２抗体及びその使用
IL307744A (en) 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CN113361141B (zh) * 2021-07-11 2022-02-18 西南石油大学 一种dna图谱算法的改进试验方法
PE20240727A1 (es) 2021-08-27 2024-04-15 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos
CA3231632A1 (en) 2021-09-15 2023-03-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
CA3235358A1 (en) 2021-10-18 2023-04-27 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
AU2022378932A1 (en) 2021-10-27 2024-05-02 Assistance Publique Hopitaux De Marseille Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
EP4177266A1 (de) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralisierende humane anti-sars-cov-2-antikörper
TW202329936A (zh) 2021-11-18 2023-08-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與parp1選擇性抑制劑之組合
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
TW202334231A (zh) 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例
TW202339805A (zh) 2021-12-28 2023-10-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atr抑制劑之組合
WO2023126822A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
WO2023166081A1 (en) 2022-03-02 2023-09-07 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
WO2023175483A1 (en) 2022-03-16 2023-09-21 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody‑drug conjugate therapy
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024072893A1 (en) 2022-09-28 2024-04-04 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
WO2024074498A1 (en) 2022-10-04 2024-04-11 Imcheck Therapeutics Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JPS6033453B2 (ja) * 1978-08-17 1985-08-02 富士電機株式会社 魚切断加工自動化装置
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6014678A (ja) * 1983-07-04 1985-01-25 Taiheiyo Kogyo Kk 電磁弁
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
DK554986A (da) * 1986-11-19 1988-07-18 Novo Industri As Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JP3121823B2 (ja) * 1988-02-12 2001-01-09 ビーティージー・インターナショナル・リミテッド 抗体におけるまたは抗体に関する改良
WO1989009622A1 (en) * 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
JP5598363B2 (ja) 2011-02-15 2014-10-01 ソニー株式会社 記憶装置およびその動作方法

Also Published As

Publication number Publication date
CA2328851C (en) 2002-08-13
EP1477497A1 (de) 2004-11-17
DK174317B1 (da) 2002-12-02
NL300279I2 (nl) 2007-10-01
EP0451216A4 (en) 1992-01-02
ES2136760T3 (es) 1999-12-01
IL162181A (en) 2006-04-10
DE10075005I1 (de) 2000-11-23
EP0682040B1 (de) 1999-08-25
WO1990007861A1 (en) 1990-07-26
NL300023I1 (nl) 2001-01-02
NO2007006I1 (no) 2007-05-07
DE68929061T2 (de) 2000-04-27
FI108797B (fi) 2002-03-28
LU90411I2 (fr) 1999-09-02
JP2003245090A (ja) 2003-09-02
SI8912489B (sl) 2000-04-30
LU90528I2 (fr) 2000-04-11
EP0939127A3 (de) 2004-07-21
YU48700B (sh) 1999-07-28
DE68929061D1 (de) 1999-09-30
NO2001025I2 (no) 2005-03-21
ATE183753T1 (de) 1999-09-15
MC2146A1 (fr) 1992-02-18
JPH04502408A (ja) 1992-05-07
NZ314793A (en) 1999-11-29
EP0939127A2 (de) 1999-09-01
ES2523810T1 (es) 2014-12-01
ES2523810T3 (es) 2015-01-12
HU211174A9 (en) 1995-11-28
LU90676I2 (fr) 2001-02-05
ES2081974T3 (es) 1996-03-16
DE04076438T1 (de) 2014-02-27
EP1491556A1 (de) 2004-12-29
ES2492815T1 (es) 2014-09-10
HRP920500B1 (en) 1999-12-31
NO2001026I2 (no) 2006-11-20
EP0451216A1 (de) 1991-10-16
EP0451216B1 (de) 1996-01-24
NO2005026I1 (no) 2005-12-27
DE10075038I1 (de) 2001-03-01
ES2492815T3 (es) 2014-10-08
DK119191D0 (da) 1991-06-19
DE98204240T1 (de) 2014-08-21
NL990020I2 (nl) 1999-11-01
NL300173I1 (nl) 2005-04-01
NL990020I1 (nl) 1999-09-01
NO2009026I1 (no) 2009-11-30
JP2007145863A (ja) 2007-06-14
NL300005I2 (nl) 2000-10-02
NO2006009I2 (no) 2009-12-07
EP1477497B1 (de) 2014-11-26
DE68925536D1 (de) 1996-03-07
CN1043875A (zh) 1990-07-18
PT92758A (pt) 1990-06-29
SG78258A1 (en) 2001-02-20
KR910700350A (ko) 1991-03-14
NO912385D0 (no) 1991-06-19
ES2081974T5 (es) 2012-10-29
EP0682040A1 (de) 1995-11-15
DE19975047I2 (de) 2008-07-03
EP0451216B9 (de) 2012-09-26
PT92758B (pt) 1996-01-31
IE20000331A1 (en) 2001-02-21
NO912385L (no) 1991-06-19
DE122005000057I1 (de) 2009-04-09
DE68925536T4 (de) 1996-09-19
ES2440825T1 (es) 2014-01-30
NZ231984A (en) 1997-06-24
KR0178385B1 (ko) 1999-04-01
NL300239I1 (nl) 2006-10-02
LU91627I2 (fr) 2010-02-09
CZ418691A3 (en) 1993-10-13
ZA899956B (en) 1990-10-31
JP2009165488A (ja) 2009-07-30
DE122005000007I1 (de) 2005-06-30
CN1057013C (zh) 2000-10-04
HK1014718A1 (en) 1999-09-30
IL92904A0 (en) 1990-09-17
DE122005000057I2 (de) 2009-07-16
DK119191A (da) 1991-06-19
EP1491556B1 (de) 2014-04-30
LU91333I2 (fr) 2007-06-11
RU2126046C1 (ru) 1999-02-10
DK199800941A (da) 1998-07-16
NO2005026I2 (no) 2009-01-19
HRP920500A2 (en) 1996-04-30
DE122005000007I2 (de) 2009-06-25
NL300239I2 (nl) 2007-03-01
NO2007006I2 (no) 2009-12-07
DD296964A5 (de) 1991-12-19
SI8912489A (sl) 1999-02-28
NO2006009I1 (no) 2006-08-07
NL300173I2 (nl) 2006-05-01
NL300279I1 (nl) 2007-07-02
FI912436A0 (fi) 1991-05-20
AU5153290A (en) 1990-08-13
EP2341080A1 (de) 2011-07-06
NL300426I1 (nl) 2010-02-01
DE122007000037I1 (de) 2007-08-02
IL162181A0 (en) 2005-11-20
DE04076439T1 (de) 2014-12-18
NL300005I1 (nl) 2000-04-03
BG61095B2 (en) 1996-10-31
CA2006865A1 (en) 1990-06-28
EP0939127B1 (de) 2014-09-17
JP2003245091A (ja) 2003-09-02
CA2006865C (en) 2002-08-20
LU91272I2 (fr) 2006-10-09
JP3604058B2 (ja) 2004-12-22
JPH114694A (ja) 1999-01-12
YU248989A (en) 1991-10-31
DE122006000036I1 (de) 2007-04-19
NO2005005I2 (no) 2009-01-19
ES2440825T3 (es) 2014-05-19
NO2001024I1 (no) 2002-01-21
FR14C0070I1 (fr) 2014-10-24
DE68925536T2 (de) 1996-06-20
NL300213I2 (nl) 2006-07-03
LU91139I2 (fr) 2005-04-04
DE68925536T3 (de) 2012-11-22
NO310473B1 (no) 2001-07-09
DE10075005I2 (de) 2005-06-23
EP0451216B2 (de) 2012-06-13
DE122009000071I1 (de) 2010-03-25
NL300213I1 (nl) 2006-02-01
DE10075038I2 (de) 2004-08-12
JP2828340B2 (ja) 1998-11-25
LU91208I2 (fr) 2006-02-28
CA2328851A1 (en) 1990-06-28
NL300023I2 (nl) 2001-09-03
AU647383B2 (en) 1994-03-24

Similar Documents

Publication Publication Date Title
ATE133452T1 (de) Humanisierte immunglobuline, deren herstellung und verwendung